high mobility group nucleosomal binding domain 2 pseudogene 40Genealiases: []
Q-omics provides the consensus-scored HMGN2P40 profile across patient tissues and cancer cell-line models. HMGN2P40 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HMGN2P40 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, HMGN2P40 RNA expression shows 13,240 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where HMGN2P40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN2P40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN2P40 survival associations across molecular data types. HMGN2P40 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN2P40 RNA expression–survival associations across cancer types. High HMGN2P40 expression shows unfavorable associations in UVM and PAAD, but favorable associations in KIRC, CESC, UCS and PRAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HMGN2P40 RNA expression.
This table summarizes HMGN2P40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN2P40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN2P40 shows lower tumor expression in THCA, READ, BRCA, UCEC and PRAD and higher tumor expression in KIRC. The KIRC box plot shows higher HMGN2P40 RNA expression in tumor versus normal tissue (log2 FC = +0.405, t-test p < 0.001).
This table shows molecular features associated with HMGN2P40 in patient tissues and cancer cell lines. In patient samples, HMGN2P40 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
